MATTHEW J PFEFFER Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for MATTHEW J PFEFFER.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of MATTHEW J PFEFFER. MATTHEW J PFEFFER is V.P. & Chief Financial Officer in CELL GENESYS INC ($CEGE) and Director in SECOND SIGHT MEDICAL PRODUCTS INC ($EYES) and CEO, CFO, Director in MANNKIND CORP ($MNKD) and Corporate VP and CFO in MANNKIND CORP ($MNKD) and Director in MANNKIND CORP ($MNKD).
Latest Insider Trading Transactions of MATTHEW J PFEFFER
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, CEGE, MNKD, EYES
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 05 2019 | EYES | SECOND SIGHT MEDIC ... | PFEFFER MATTHEW J | Director | Option Exercise | A | 0.71 | 56,685 | 40,178 | 56,685 | |
| Jun 05 2018 | EYES | SECOND SIGHT MEDIC ... | PFEFFER MATTHEW J | Director | Option Exercise | A | 2.05 | 25,970 | 53,239 | 25,970 | |
| Jun 05 2018 | EYES | SECOND SIGHT MEDIC ... | PFEFFER MATTHEW J | Director | Grant | A | 0.00 | 35,533 | 0 | 118,301 | 82.8 K to 118.3 K (+42.93 %) |
| Jun 05 2018 | EYES | SECOND SIGHT MEDIC ... | PFEFFER MATTHEW J | Director | Option Exercise | A | 2.05 | 25,970 | 53,239 | 25,970 | |
| Jun 05 2018 | EYES | SECOND SIGHT MEDIC ... | PFEFFER MATTHEW J | Director | Grant | A | 0.00 | 35,533 | 0 | 118,301 | 82.8 K to 118.3 K (+42.93 %) |
| Aug 29 2017 | MNKD | MANNKIND CORP | PFEFFER MATTHEW J | Director | Payment of Exercise | F | 1.55 | 303 | 470 | 81,961 | 82.3 K to 82 K (-0.37 %) |
| Aug 23 2017 | MNKD | MANNKIND CORP | PFEFFER MATTHEW J | Director | Payment of Exercise | F | 1.41 | 170 | 240 | 82,264 | 82.4 K to 82.3 K (-0.21 %) |
| Aug 23 2017 | MNKD | MANNKIND CORP | PFEFFER MATTHEW J | Director | Payment of Exercise | F | 1.46 | 183 | 267 | 82,434 | 82.6 K to 82.4 K (-0.22 %) |
| Aug 23 2017 | MNKD | MANNKIND CORP | PFEFFER MATTHEW J | Director | Buy | P | 1.23 | 2,000 | 2,460 | 82,617 | 80.6 K to 82.6 K (+2.48 %) |
| Jun 05 2017 | EYES | SECOND SIGHT MEDIC ... | PFEFFER MATTHEW J | Director | Grant | A | 1.17 | 59,725 | 69,998 | 82,768 | 23 K to 82.8 K (+259.19 %) |
| Mar 16 2017 | EYES | SECOND SIGHT MEDIC ... | PFEFFER MATTHEW J | Director | Option Exercise | A | 1.47 | 5,582 | 8,206 | 5,582 | |
| Mar 16 2017 | EYES | SECOND SIGHT MEDIC ... | PFEFFER MATTHEW J | Director | Grant | A | 1.47 | 5,582 | 8,206 | 23,043 | 17.5 K to 23 K (+31.97 %) |
| Jan 04 2017 | MNKD | MANNKIND CORP | PFEFFER MATTHEW J | CEO, CFO, Director | Buy | P | 0.54 | 4,540 | 2,452 | 403,085 | 398.5 K to 403.1 K (+1.14 %) |
| Aug 16 2016 | MNKD | MANNKIND CORP | PFEFFER MATTHEW J | CEO, CFO, Director | Buy | P | 0.99 | 25,000 | 24,650 | 397,996 | 373 K to 398 K (+6.70 %) |
| Jun 03 2016 | EYES | SECOND SIGHT MEDIC ... | PFEFFER MATTHEW J | Director | Grant | A | 3.95 | 17,461 | 68,997 | 17,461 | 0 to 17.5 K |
| Feb 29 2016 | MNKD | MANNKIND CORP | PFEFFER MATTHEW J | CEO, CFO, Director | Option Exercise | A | 0.92 | 1,345,300 | 1,237,676 | 1,345,300 | |
| Feb 29 2016 | MNKD | MANNKIND CORP | PFEFFER MATTHEW J | CEO, CFO, Director | Option Exercise | A | 0.92 | 604,267 | 555,926 | 604,267 | |
| Sep 03 2015 | MNKD | MANNKIND CORP | PFEFFER MATTHEW J | Corporate VP and CF ... | Option Exercise | A | 3.91 | 72,300 | 282,693 | 72,300 | |
| Sep 03 2015 | MNKD | MANNKIND CORP | PFEFFER MATTHEW J | Corporate VP and CF ... | Grant | A | 0.00 | 16,100 | 0 | 372,996 | 356.9 K to 373 K (+4.51 %) |
| Sep 03 2015 | MNKD | MANNKIND CORP | PFEFFER MATTHEW J | Corporate VP and CF ... | Payment of Exercise | F | 3.79 | 846 | 3,206 | 356,896 | 357.7 K to 356.9 K (-0.24 %) |
| Sep 03 2015 | MNKD | MANNKIND CORP | PFEFFER MATTHEW J | Corporate VP and CF ... | Payment of Exercise | F | 3.79 | 912 | 3,456 | 357,742 | 358.7 K to 357.7 K (-0.25 %) |
| Sep 03 2015 | MNKD | MANNKIND CORP | PFEFFER MATTHEW J | Corporate VP and CF ... | Payment of Exercise | F | 4.15 | 1,598 | 6,632 | 358,654 | 360.3 K to 358.7 K (-0.44 %) |
| Sep 03 2015 | MNKD | MANNKIND CORP | PFEFFER MATTHEW J | Corporate VP and CF ... | Payment of Exercise | F | 4.09 | 1,598 | 6,536 | 360,252 | 361.9 K to 360.3 K (-0.44 %) |
| Feb 25 2015 | MNKD | MANNKIND CORP | PFEFFER MATTHEW J | Corporate VP and CF ... | Option Exercise | M | 2.86 | 60,000 | 171,600 | 60,000 | |
| Feb 25 2015 | MNKD | MANNKIND CORP | PFEFFER MATTHEW J | Corporate VP and CF ... | Payment of Exercise | F | 6.43 | 5,975 | 38,419 | 361,850 | 367.8 K to 361.9 K (-1.62 %) |
| Feb 25 2015 | MNKD | MANNKIND CORP | PFEFFER MATTHEW J | Corporate VP and CF ... | Grant | A | 0.00 | 15,000 | 0 | 367,825 | 352.8 K to 367.8 K (+4.25 %) |
| Aug 04 2003 | CEGE | CELL GENESYS INC | PFEFFER MATTHEW J | V.P. & Chief Financ ... | Buy | J | 8.08 | 361 | 2,918 | 22,503 | 22.1 K to 22.5 K (+1.63 %) |
Page: 1